Authored by Karl Simpson
At the beginning of 2013 Liftstream profiled 13 life science leaders we believed were going to make an impact over the course of the year. Below we outline how Mr David Mott performed for NEA in 2013.
2013 Liftstream Analysis: NEA scored big in 2012 with a new $2.6bn fund, outstripping all others. This year they start putting that money to work by looking for healthcare and more specifically biopharma investments. The industry has had some capital supply issues in recent years and to have a significant fund like this getting active means it will be interesting to see where that capital is placed.
• Strategic deal selection
• Selecting the right management teams for portfolio companies
• Looking for international opportunities
2014 Liftstream Verdict: One of the companies selected for investment by David Mott this year was Cydan Corporation. Cydan combined two of the key strategic objectives we look at this time last year as NEA was working to put its fund to work. Cydan was a company started from scratch with an experienced team led by Cristina Csimma as CEO. Cydan’s aim is to act as a drug development accelerator for rare disease drugs which will be de-risked and developed ready for licensing. It is a company which has partnered with KLS Partners, a European venture capital firm who have rare diseases interests and NEA provided them with some funding toward the first closing of their fund announced in 2013.
To see how the other leaders profiled in Liftstream’s 13 for 2013 performed please click here. Liftstream would very much like to hear your thoughts on how you believe these life science leaders performed in 2013. Please leave your comments below, email email@example.com or tweet @liftstream #LSL13for13
Liftstream is an executive search and interim management recruitment company working exclusively within the global life sciences sector.